Tag: sessions

The Government of Canada launches public consultations on the future of Billy Bishop Toronto City Airport

TORONTO, June 8, 2026 /CNW/ - Billy Bishop Toronto City Airport is an important part of Canada's air transportation network. It supports jobs, tourism,...

PPMW launches summer Spill the Tea ambassadorship for Black Women

WASHINGTON, June 8, 2026 /PRNewswire/ -- In May, Planned Parenthood of Metropolitan Washington, DC launched the most recent cohort of its Spill the Tea...

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

Châtillon, France, June 8, 2026

AG1 LAUNCHES AG1 PRO WITH CREATINE AND MORE FOR ADVANCED MUSCLE AND GUT SUPPORT

AG1 Pro's advanced formula builds on AG1's clinically-backed formula to include additional research-backed key ingredients, including creatine, that target muscle strength, metabolic resilience, and...

Remote Browser Isolation Solutions Market to Reach USD 6.53 Billion by 2031, Driven by Zero-Trust Security Adoption | Valuates Reports

BANGALORE, India, June 8, 2026 /PRNewswire/ -- ...

Remote Browser Isolation Solutions Market to Reach USD 6.53 Billion by 2031, Driven by Zero-Trust Security Adoption | Valuates Reports

BANGALORE, India, June 8, 2026 /PRNewswire/ -- ...

Agent Governance Platform from Ares® Networks Now Available in the Microsoft Marketplace

Microsoft Azure customers worldwide can now discover and deploy the Ares® Networks Agent Governance Platform through Microsoft Marketplace, accessing trusted solutions that accelerate innovation...

AutoFull Powers IEM Cologne 2026 with Next-Gen Gaming Chairs

COLOGNE, Germany, June 8, 2026 /PRNewswire/ -- AutoFull, a well-known brand of professional esports furniture, has announced its partnership with the IEM Cologne Major 2026,...

DL Holdings’ Fourth “Victoria Harbour Night Talk”: The AI Wave: Global Investment & Hong Kong Opportunities

HONG KONG, June 8, 2026 /PRNewswire/ -- The Fourth "Victoria Harbour Night Talk" concluded successfully on June 5 at Cloud 39, The Henderson, Central,...

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.^2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),²and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).⁴ Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.^5,6

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsSessions

MDP Enters OLIVE YOUNG

Harness Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Parkinson’s Disease Programme

GEHPA-APAC Alliance Officially Launched to Advance Inclusive & Intelligent Education and Healthcare

Tag: sessions

The Government of Canada launches public consultations on the future of Billy Bishop Toronto City Airport

PPMW launches summer Spill the Tea ambassadorship for Black Women

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

AG1 LAUNCHES AG1 PRO WITH CREATINE AND MORE FOR ADVANCED MUSCLE AND GUT SUPPORT

Remote Browser Isolation Solutions Market to Reach USD 6.53 Billion by 2031, Driven by Zero-Trust Security Adoption | Valuates Reports

Remote Browser Isolation Solutions Market to Reach USD 6.53 Billion by 2031, Driven by Zero-Trust Security Adoption | Valuates Reports

Agent Governance Platform from Ares® Networks Now Available in the Microsoft Marketplace

AutoFull Powers IEM Cologne 2026 with Next-Gen Gaming Chairs

DL Holdings’ Fourth “Victoria Harbour Night Talk”: The AI Wave: Global Investment & Hong Kong Opportunities

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us